OncoNano Medicine

OncoNano Medicine logo

Founded in 2016, OncoNano Medicine, located in Southlake, Texas, is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. This variability is a proven, simple, and effective identifier of diseased tissue, providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents. The company’s lead program, ONM-100, targets tumor acidosis to accurately differentiate cancer from healthy tissue for use in surgery. This technology got its start as a UT Southwestern collaboration between a cancer surgeon and a scientist with expertise in biomedical engineering and pharmacology.